Distinquishing the Afferent Sensitization of GVHD from GVL/GVT at the Level of H
在 H 水平上区分 GVHD 和 GVL/GVT 的传入敏化
基本信息
- 批准号:9067216
- 负责人:
- 金额:$ 30.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AddressAllogenicAllograftingAntigen PresentationAntigen-Presenting CellsBloodDendritic CellsFreedomGraft RejectionHematopoietic Stem Cell TransplantationHumanIL6 geneImmuneImmune responseImmunityImmunobiologyImmunosuppressionIn VitroInstructionInterleukin-15JAK2 geneLeadLymphocyteMarrowMessenger RNAModelingMorbidity - disease rateMusNatural Killer CellsOrgan TransplantationPathway interactionsPharmaceutical PreparationsPopulation HeterogeneityPreventionPublic HealthReactionRelapseSTAT3 geneSignal TransductionSolidStem cell transplantT-LymphocyteTransplant RecipientsTransplantationTumor Immunitybasecytokinegraft vs host diseasegraft vs leukemia effectimprovedin vivoleukemiamonocytemortalitynovel strategiespreventtumor
项目摘要
This project addresses two major barriers to progress in allogeneic hematopoietic stem cell transplantation
(HSCT): graft-vs-host disease (GvHD) and relapse. A novel strategy is proposed that challenges the
prevailing practice of trying to curtail donor T cell alloreactivity after the fact, to one of controlling the afferent
sensitization of lymphocyte effectors at the level of antigen-presentation by dendritic cells (DCs). DCs
comprise a heterogeneous population of potent antigen-presenting cells, which initiate immunity and control
its quality. We hypothesize that the undesirable complications of GvHD can be separated from the beneficial
GvL effects exerted by allogeneic HSCT, based on differences in afferent sensitization of immune responses
by distinct DC subtypes. This hypothesis will be addressed in the following specific aims: SPECIFIC AIM 1:
Determine whether allogeneic interactions between human Langerhans-type DCs (LCs) and T cells in vitro
are abrogated by inhibition of JAK2-STAT3 signaling, and whether the capacity of WTI mRNA-
electroporated LCs remains intact to break tolerance against this self-differentiation tumor Ag by an IL15-
dependent mechanism. SPECIFIC AIM 2: Compare and contrast the inhibition of JAK2-STAT3 in NK cells
stimulated by monocyte-derived DCs (moDCs) via an IL12p70-dependent mechanism, with JAK2 inhibition
of moDC-stimulated allogeneic T cells. SPECIFIC AIM 3: Evaluate the mechanism of JAK2 inhibition with
respect to alloreactivity and tumor immunity in defined mouse transplant models. Successful inhibition of the
JAK2-pSTAT3 pathway, which would block at least moDC-derived IL6 and IL23 cytokine effects on
alloreactive lymphocytes, would lead to the use of an entirely new class of drugs for prevention and
treatment of GvHD. This would maintain freedom from relapse (GvL) and infectious morbidity and mortality
brought on by less selective immune suppression. The approach would also take full advantage of the
potency of W T I mRNA-electroporated LCs to break tolerance and stimulate effective CTLs against this
broadly-expressed, self-differentiation tumor Ag. Successful completion ofthese aims will fundamentally
alter management of graft-host interactions in the context of allogeneic HSCT by controlling immune
responses regulated by distinct DC subsets from their onset. These studies will also have broader public
health potential to improve management of immune suppression and prevention of graft rejection in solid
organ transplantation.
该项目解决了同种异性造血干细胞移植的两个主要障碍
(HSCT):移植-VS宿主病(GVHD)和复发。提出了一种新的策略,挑战
事实后,试图减少供体T细胞出色反应性的盛行练习是控制传入的一种
树突状细胞(DC)在抗原呈递水平上淋巴细胞效应子的敏化。 DCS
包括有效抗原呈递细胞的异质种群,启动免疫力和控制
它的质量。我们假设GVHD的不良并发症可以与有益的
基于免疫反应的传入敏感性差异,同种异体HSCT产生的GVL效应
通过不同的直流亚型。该假设将在以下特定目的中解决:具体目的1:
确定在体外人类Langerhans型DC(LCS)和T细胞之间的同种异体相互作用是否相互作用
通过抑制JAK2-STAT3信号传导消除,WTI mRNA-的能力是否能力
电穿孔的LCS仍然完好无损,可以通过IL15-损坏对这种自定义肿瘤Ag的耐受性。
依赖机制。特定目标2:比较和对比NK细胞中JAK2-STAT3的抑制
通过IL12P70依赖性机制,由单核细胞衍生的DC(MODC)刺激,JAK2抑制
MODC刺激的同种异体T细胞。特定目标3:评估JAK2抑制的机制
在定义的小鼠移植模型中,相对于同种反应性和肿瘤免疫。成功抑制
JAK2-PSTAT3途径,它将至少阻止MODC衍生的IL6和IL23细胞因子对
同种异体淋巴细胞将导致使用全新的药物进行预防和
GVHD的处理。这将保持免于复发(GVL)和传染性发病率和死亡率的自由
由较少选择性免疫抑制带来。该方法还将充分利用
w t i mRNA - 电载体的LCS的效力,以破坏耐受性并刺激有效的CTL
广泛表达的,自分配的肿瘤AG。成功完成这些目标将从根本上
通过控制免疫,在同种异体HSCT的背景下改变了移植物 - 宿主相互作用的管理
响应由不同的DC子集从其发作中调节。这些研究也将有更广泛的公众
健康潜力,以改善固体中免疫抑制和预防移植排斥的治疗
器官移植。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James William Young其他文献
James William Young的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James William Young', 18)}}的其他基金
HUMAN DENDRITIC CELLS AND THE ONSET OF INNATE AND ADAPTIVE IMMUNITY IN ALLOGENEIC
人类树突细胞和同种异体中先天性和适应性免疫的发生
- 批准号:
7318390 - 财政年份:2007
- 资助金额:
$ 30.54万 - 项目类别:
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
人类树突细胞的基因修饰以增强癌症免疫能力
- 批准号:
8120855 - 财政年份:2007
- 资助金额:
$ 30.54万 - 项目类别:
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
人类树突细胞的基因修饰以增强癌症免疫能力
- 批准号:
7415210 - 财政年份:2007
- 资助金额:
$ 30.54万 - 项目类别:
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
人类树突细胞的基因修饰以增强癌症免疫能力
- 批准号:
7266455 - 财政年份:2007
- 资助金额:
$ 30.54万 - 项目类别:
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
人类树突细胞的基因修饰以增强癌症免疫能力
- 批准号:
8215911 - 财政年份:2007
- 资助金额:
$ 30.54万 - 项目类别:
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
人类树突细胞的基因修饰以增强癌症免疫能力
- 批准号:
7576916 - 财政年份:2007
- 资助金额:
$ 30.54万 - 项目类别:
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
人类树突细胞的基因修饰以增强癌症免疫能力
- 批准号:
7765556 - 财政年份:2007
- 资助金额:
$ 30.54万 - 项目类别:
Immune responses to gene-modified, autologous dendritic cell vaccines in melanoma
黑色素瘤中基因修饰的自体树突状细胞疫苗的免疫反应
- 批准号:
7244117 - 财政年份:2006
- 资助金额:
$ 30.54万 - 项目类别:
Immune responses to gene-modified, autologous dendritic cell vaccines in melanoma
黑色素瘤中基因修饰的自体树突状细胞疫苗的免疫反应
- 批准号:
7111373 - 财政年份:2006
- 资助金额:
$ 30.54万 - 项目类别:
相似国自然基金
肿瘤球混合堆砌-诱导分化构建同源性血管化结肠癌类器官用于血管发生干预靶点筛选
- 批准号:82373453
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
非小细胞肺癌中靶向抑制同源性重组修复增敏免疫检查点抑制剂疗效的研究和机制探索
- 批准号:82103045
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
非小细胞肺癌中靶向抑制同源性重组修复增敏免疫检查点抑制剂疗效的研究和机制探索
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
FHF2对肥厚心肌钙致钙释放的影响及其机制研究
- 批准号:81900249
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
PTEN通过激活细胞程序性坏死通路促进APP淀粉样蛋白代谢的机制研究
- 批准号:81901116
- 批准年份:2019
- 资助金额:20.5 万元
- 项目类别:青年科学基金项目
相似海外基金
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 30.54万 - 项目类别:
Development of a Novel Bone Adhesive Scaffold to Accelerate Bone Regeneration and Improve Ridge Height Maintenance for the Treatment of Patients with Residual Ridge Resorption
开发新型骨粘合剂支架以加速骨再生并改善牙槽嵴高度维持以治疗残留牙槽嵴吸收的患者
- 批准号:
10603678 - 财政年份:2023
- 资助金额:
$ 30.54万 - 项目类别:
Determining the Efficacy of a Novel Apatite-Based Antimicrobial Bone Scaffold for Craniofacial Surgical Applications
确定新型磷灰石抗菌骨支架在颅面外科应用中的功效
- 批准号:
10573777 - 财政年份:2023
- 资助金额:
$ 30.54万 - 项目类别:
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts
评估天然和 3D 打印同种异体移植物中不同人类细胞类型的免疫原性和抗原性
- 批准号:
10353416 - 财政年份:2021
- 资助金额:
$ 30.54万 - 项目类别:
Mechanisms whereby IFN-gamma sensitizes AML to the graft-vs-leukemia effect
IFN-γ 使 AML 对移植物抗白血病效应敏感的机制
- 批准号:
10394937 - 财政年份:2021
- 资助金额:
$ 30.54万 - 项目类别: